U.S. markets closed
  • S&P Futures

    4,349.75
    +6.50 (+0.15%)
     
  • Dow Futures

    33,849.00
    +51.00 (+0.15%)
     
  • Nasdaq Futures

    15,034.25
    +10.25 (+0.07%)
     
  • Russell 2000 Futures

    2,185.50
    +4.60 (+0.21%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,778.20
    0.00 (0.00%)
     
  • Silver

    22.77
    +0.16 (+0.73%)
     
  • EUR/USD

    1.1722
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3650
    -0.0014 (-0.11%)
     
  • USD/JPY

    109.4620
    +0.2420 (+0.22%)
     
  • BTC-USD

    42,203.91
    -448.77 (-1.05%)
     
  • CMC Crypto 200

    1,044.67
    -19.18 (-1.80%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,681.95
    -157.76 (-0.53%)
     

Seer to Present at the Cowen 41st Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.

Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 3 at 8:40 a.m. Pacific Time / 11:40 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer™ is a life sciences company focused on enabling exceptional scientific outcomes by commercializing transformative products that will drive breakthrough ideas by unlocking the deep, unbiased biological information that can make them a reality. Seer is developing its Proteograph™ Product Suite, which is an integrated solution consisting of consumables, automation instrumentation and proprietary software that performs deep, unbiased proteomics analysis at scale in a matter of hours. Seer designed the Proteograph to be efficient and easy-to-use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution broadly available to life sciences researchers. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio